A Study of RO6927005 Either As Monotherapy (Part A) or in Combination With Gemcitabine and Nab-Paclitaxel (Part B) to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Clinical Activity in Patients With Mesothelin-positive Metastatic and/or Locally Advanced Malignant Solid Tumors

NCT02317419 · clinicaltrials.gov ↗
PHASE1
Phase
TERMINATED
Status
15
Enrollment
INDUSTRY
Sponsor class

Stopped The study was prematurely terminated because the emerging benefit:risk ratio did not justify continuing dosing patients.

Conditions

Interventions

Sponsor

Hoffmann-La Roche